PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance...

Full description

Saved in:
Bibliographic Details
Published in:Cell death & disease 2020-09, Vol.11 (9), p.797-797, Article 797
Main Authors: Liu, Rui, Chen, Youwen, Liu, Guangzhi, Li, Chenxi, Song, Yurong, Cao, Zhiwen, Li, Wen, Hu, Jinghong, Lu, Cheng, Liu, Yuanyan
Format: Article
Language:English
Subjects:
Cell Proliferation
Drug Resistance, Multiple - genetics
Humans
Neoplasms - drug therapy
Neoplasms - genetics
Proto-Oncogene Proteins c-akt - metabolism
Review
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism. This review highlights the aberrant activation of PI3K/AKT as a key link that modulates MDR. We summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway, which is further related to MDR, including the expression of apoptosis-related protein, ABC transport and glycogen synthase kinase-3 beta (GSK-3β), synergism with nuclear factor kappa beta (NF-κB) and mammalian target of rapamycin (mTOR), and the regulation of glycolysis.
ISSN:2041-4889
2041-4889
DOI:10.1038/s41419-020-02998-6